Cigna/The Cigna Group v. Celgene/BMS
antitrust follow-on litigationAntitrust complaint referencing the '647/'648/'649 crystal-form patents as part of an alleged scheme.
Defendant
2 cases as defendant.
I'll verify the company's profile with web searches.
Let me verify the CenterWell case and BMS corporate details.
Celgene Corporation / Bristol Myers Squibb (BMS)
Celgene Corporation is a Delaware-incorporated biopharmaceutical company with its principal place of business at 86 Morris Avenue, Summit, New Jersey. Founded in 1986, it was acquired by Bristol Myers Squibb (NYSE: BMY) in November 2019 and now operates as a wholly owned BMS subsidiary (as stated in the Cigna complaint, S.D.N.Y. 1:25-cv-05237). Pre-acquisition Celgene reported $15.28 billion in 2018 revenue and about 8,850 employees. Parent BMS is headquartered in Princeton, New Jersey, reported $48.2 billion in 2025 revenue, and employs roughly 32,500 people globally. Note that the case database labels the entity "Celgene/BMS," combining the subsidiary with its parent; both are named together as defendants.
Products / operations
Celgene commercializes oncology and immunology therapies, its principal legacy franchises being Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), and Thalomid (thalidomide) — all used in multiple myeloma and related blood cancers. These products are now part of BMS's broader portfolio alongside Opdivo, Eliquis, Orencia, and cell therapies such as Breyanzi and Abecma. This is an operating company with real products and sales, not a non-practicing entity.
Patent-litigation posture
Both tracked matters place the company as a defendant (0 plaintiff, 2 defendant), consistent with an operating company being sued rather than asserting patents. Notably, these are antitrust suits, not patent infringement suits: both were filed by pharmacy-benefit/payor plaintiffs in the U.S. District Court for the Southern District of New York. The dataset does not capture Celgene's own Hatch-Waxman infringement suits against generic manufacturers, which are referenced only as background allegations in these complaints.
Notable cases
CenterWell Pharmacy, Inc. v. Celgene Corporation (S.D.N.Y., 1:24-cv-06924, filed September 13, 2024) and The Cigna Group v. Celgene Corporation et al. (S.D.N.Y., 1:25-cv-05237, filed June 24, 2025) both allege Sherman Act §2 monopolization of the pomalidomide/Pomalyst market via sham patent litigation and "pay-for-delay" settlements. Both are related to Louisiana Health Service & Indemnity Co. v. Celgene (1:23-cv-07871). Allegations are unproven; the merits are not assessed here.
Antitrust complaint referencing the '647/'648/'649 crystal-form patents as part of an alleged scheme.
Antitrust complaint referencing the '647/'648/'649 crystal-form patents as part of an alleged scheme.